NASDAQ:GNPX Genprex (GNPX) Stock Price, News & Analysis → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Free GNPX Stock Alerts $2.15 -0.06 (-2.71%) (As of 01:06 PM ET) Add Compare Share Share Today's Range$2.11▼$2.2450-Day Range$2.13▼$4.7052-Week Range$2.09▼$42.40Volume6,974 shsAverage Volume71,414 shsMarket Capitalization$4.11 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Genprex alerts: Email Address Genprex MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside365.1% Upside$10.00 Price TargetShort InterestHealthy2.69% of Float Sold ShortDividend StrengthN/ASustainability-0.78Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($5.77) to ($2.78) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.28 out of 5 stars 3.5 Analyst's Opinion Consensus RatingGenprex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageGenprex has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.69% of the float of Genprex has been sold short.Short Interest Ratio / Days to CoverGenprex has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Genprex has recently decreased by 29.00%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldGenprex does not currently pay a dividend.Dividend GrowthGenprex does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGenprex has received a 75.22% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for cancer", "Clinical research services for physiological diseases ", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Genprex is -0.78. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Genprex this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for GNPX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows4 people have added Genprex to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genprex insiders have not sold or bought any company stock.Percentage Held by Insiders11.54% of the stock of Genprex is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 14.05% of the stock of Genprex is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Genprex are expected to grow in the coming year, from ($5.77) to ($2.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Genprex is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Genprex is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGenprex has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceThe Next Nvidia?The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.Go here now for this breaking story. About Genprex Stock (NASDAQ:GNPX)Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.Read More GNPX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GNPX Stock News HeadlinesApril 9, 2024 | finance.yahoo.comGenprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual MeetingApril 9, 2024 | prnewswire.comGenprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual MeetingApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.April 3, 2024 | markets.businessinsider.comGenprex Expands Trial Sites For Reqorsa Therapy-Tecentriq Trial In Small Cell Lung Cancer; Stock UpApril 3, 2024 | prnewswire.comGenprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung CancerApril 2, 2024 | markets.businessinsider.comGenprex: Collaborators Report Positive Preclinical Data With NPRL2 Gene TherapyApril 2, 2024 | prnewswire.comGenprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery SystemMarch 22, 2024 | prnewswire.comGenprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.March 21, 2024 | marketwatch.comGenprex Shares Drop 12% on Latest Stock Offering to Get Proceeds of $5.8MMarch 20, 2024 | marketwatch.comGenprex Shares Hit 52-Week Low After Direct Offering PricesMarch 19, 2024 | prnewswire.comGenprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMarch 19, 2024 | finanznachrichten.deGenprex, Inc.: Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMarch 19, 2024 | prnewswire.comGenprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMarch 12, 2024 | markets.businessinsider.comGenprex Granted Korean Patent For Reqorsa Therapy With Anti-PD-1, PD-L1 AntibodiesMarch 12, 2024 | finance.yahoo.comGenprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat CancersMarch 9, 2024 | theglobeandmail.comGenprex (NASDAQ: GNPX) Preclinical Data to be Presented at AACR Annual MeetingMarch 6, 2024 | prnewswire.comGenprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual MeetingFebruary 26, 2024 | theglobeandmail.comGenprex (NASDAQ: GNPX) Announces Participation at BIO CEO & Investor ConferenceFebruary 7, 2024 | markets.businessinsider.comGenprex To Expand Non-clinical Program To Study TUSC2, NPRL2February 7, 2024 | finance.yahoo.comGenprex Expands Nonclinical Programs into New Therapeutic Indications with Research CollaboratorsFebruary 6, 2024 | marketwatch.comGenprex Shares Climb After First Patient Dosing in Reqorsa-Tagrisso TrialFebruary 6, 2024 | msn.comGenprex Launches Phase 2a Reqorsa Trial ExpansionFebruary 6, 2024 | finance.yahoo.comGenprex to Present at Upcoming BIO CEO & Investor ConferenceFebruary 5, 2024 | finance.yahoo.comGenprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung CancerJanuary 31, 2024 | msn.comDow Turns Lower; Federal Reserve Keeps Rates UnchangedJanuary 31, 2024 | msn.comGenprex to effect 1-for-40 reverse stock split to regain Nasdaq complianceSee More Headlines Receive GNPX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genprex and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/01/2019Today4/25/2024Next Earnings (Estimated)5/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GNPX CUSIPN/A CIK1595248 Webwww.genprex.com Phone(877) 774-4679FaxN/AEmployees26Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+352.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($24.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,860,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-245.62% Return on Assets-185.50% Debt Debt-to-Equity RatioN/A Current Ratio2.31 Quick Ratio2.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.99 per share Price / Book0.44Miscellaneous Outstanding Shares1,910,000Free Float1,690,000Market Cap$4.22 million OptionableOptionable Beta-0.61 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. John Rodney Varner (Age 67)Co-Founder, Chairman, President & CEO Comp: $886.97kMr. Ryan M. Confer M.S. (Age 42)Chief Financial Officer Comp: $606.57kMr. David M. SchlossSenior Vice President of Human ResourcesMr. Thomas C. Gallagher Esq.Senior Vice President of Intellectual Property & LicensingDr. Mark S. Berger M.D. (Age 69)Chief Medical Officer Dr. Suzanne Thornton-JonesSenior Vice President of Regulatory Affairs & QualityDr. Jack A. Roth F.A.C.S.M.D., Chairman of Scientific & Medical Advisory BoardMore ExecutivesKey CompetitorsCingulateNASDAQ:CINGLipella PharmaceuticalsNASDAQ:LIPOTharimmuneNASDAQ:THARSeelos TherapeuticsNASDAQ:SEELZyVersa TherapeuticsNASDAQ:ZVSAView All Competitors GNPX Stock Analysis - Frequently Asked Questions Should I buy or sell Genprex stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genprex in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GNPX shares. View GNPX analyst ratings or view top-rated stocks. What is Genprex's stock price target for 2024? 1 Wall Street research analysts have issued 1-year target prices for Genprex's stock. Their GNPX share price targets range from $10.00 to $10.00. On average, they expect the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 365.1% from the stock's current price. View analysts price targets for GNPX or view top-rated stocks among Wall Street analysts. How have GNPX shares performed in 2024? Genprex's stock was trading at $9.20 on January 1st, 2024. Since then, GNPX stock has decreased by 76.6% and is now trading at $2.15. View the best growth stocks for 2024 here. Are investors shorting Genprex? Genprex saw a drop in short interest in the month of April. As of April 15th, there was short interest totaling 49,700 shares, a drop of 29.0% from the March 31st total of 70,000 shares. Based on an average daily volume of 85,900 shares, the days-to-cover ratio is currently 0.6 days. Currently, 2.7% of the shares of the company are sold short. View Genprex's Short Interest. When is Genprex's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 27th 2024. View our GNPX earnings forecast. How were Genprex's earnings last quarter? Genprex, Inc. (NASDAQ:GNPX) announced its quarterly earnings data on Monday, April, 1st. The company reported ($9.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($5.40) by $3.80. When did Genprex's stock split? Genprex's stock reverse split on Friday, February 2nd 2024. The 1-40 reverse split was announced on Friday, February 2nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of Genprex own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genprex investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), Co-Diagnostics (CODX), OPKO Health (OPK), SCYNEXIS (SCYX), iBio (IBIO) and Advanced Micro Devices (AMD). How do I buy shares of Genprex? Shares of GNPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GNPX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genprex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
